Navitor Pharmaceuticals, Inc., is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling pathways. The company’s proprietary drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. Navitor’s therapeutics are designed to selectively modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activity to address a wide range of diseases, including metabolic, CNS, autoimmune and musculoskeletal diseases, as well as several rare disorders. The company is backed by leading financial and corporate investors, including Polaris Partners, Atlas Venture, J&J Innovation - JJDC, SR One, Brace Pharma Capital, Remeditex ventures, Sanofi Ventures and The Longevity Fund.